Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe.
MIAMI LAKES, Florida— Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”
To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
- Published in Press Releases
Adimarket Set to Share Innovative Exosomes Products at Upcoming Medical Congresses
The online retailer launched its new line of products in July and will speak with physicians seeking new treatment products and protocols to alleviate patient suffering
MIAMI LAKES, Florida—Adimarket, LLC, an online marketplace for regenerative medicine practitioners and a subsidiary of the Global Stem Cells Group (GSCG), has taken to the road in a series of business trips with the intent of promoting the group’s new line of exosomes, a neonatal-derived stem cells product.
The exosomes products were launched in July 2019 in Buenos Aires, and during the weekend of August 23, Adimarket representatives were in Santiago de Chile to sponsor one of the regenerative medicine industry’s most prolific medical congresses, hosted by the Chilean Society of Aesthetic Surgery. During the event, Mr. Benito Novas, Chief Executive Officer of the Global Stem Cells Group, was on hand to officially launch the exosomes products with a lecture in the congress’ main room.
The Adimarket and GSCG teams will continue their series of business trips to introduce Adimarket’s line of exosomes products to physicians across the globe. Currently, two additional business trips are on the docket where representatives will attend two upcoming medical congresses.
On September 25, 2019 GSCG faculty members will attend the 4th International Congress of Aesthetic Gynecology in Veracruz, Mexico to be held at the Holiday Inn Hotel. One faculty member will speak to the audience about the newest exosomes products and their clinical applications.
The GSCG will also be hosting the International Cell Therapy Symposium on the University of Miami campus in Miami, Florida on October 24, 2019. The event is expected to draw a large attendance of physicians in the regenerative medicine field, and the GSCG has invited more than 10 scientists and practitioners with vast experience in regenerative medicine to host the congress’ educational sessions. At least five of the conference sessions will focus on how exosomes can help people suffering from degenerative diseases
“Adimarket, in conjunction with the Global Stem Cells Group, is pleased to be able to share its newest exosomes products with physicians across the globe practicing regenerative medicine,” said Benito Novas, CEO of the Global Stem Cells Group. “Our goal is to create groundbreaking products and treatment protocols that help physicians deliver innovative treatment options to their patients, helping to alleviate suffering caused by degenerative diseases.”
To learn more about Adimarket and its product offerings, visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group and its efforts in the field of regenerative medicine, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
ISSCA Set to Welcome 13 Speakers at Upcoming Symposium in Miami
The regenerative medicine symposium will be held on the University of Miami campus on October 24, 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA) has announced its lineup of speakers for its upcoming Regenerative Medicine Symposium. The symposium will be held on the University of Miami campus in the Donna E. Shalala Student Center on October 24, 2019 and features an impressive lineup of global authorities in regenerative medicine.
ISSCA is a global leader in stem cells research, applications, and education, partnering with major global institutions and locations worldwide to host its independent medical congresses. This year’s symposium hosted on the University of Miami campus will feature industry experts from seven countries, including Spain, Argentina, Bolivia, Colombia, Ecuador, Mexico, and the US. Some notable speakers include the following:
- Dra. Silvina Pastrana from Argentina, who serves as the Medical Director of the Stem Cells Center Buenos Aires. Dra. Pastrana will discuss her experiences in treating patients who suffer from osteoarthritis conditions.
- Dr. Pedro Sanchez hails from Colombia and is a highly regarded regenerative medicine and orthopedic specialist. He currently practices in Bogota where he offers stem cells treatments for people who suffer from orthopedic conditions.
- Dr. Miguel Guillermo Garbe of Spain serves as the president of the country’s Regenerative Medicine Association. He currently leads a seminal investigation on how to increase cardiological function in patients who have suffered from strokes.
- Dr. Roberto Blum from Ecuador has worked in the stem cells field for over 10 years and will share his industry experience with attendees.
- Dr. Victor Pereyra, an Argentinian neurosurgeon, will lecture on how ozone therapy and stem cells could help patients suffering from spinal injuries.
“The symposium will provide an informative day where physicians can learn from global leaders in the stem cells industry with the hopes of bringing new knowledge and treatment options back to their practices for their patients suffering from degenerative diseases.”
To learn more about the ISSCA and its Miami symposium, visit
http://www.stemcellsgroup.com/.- Published in Press Releases
GSCG Meets Demands of Patients Seeking Stem Cells Treatment with New Facilities
The group’s new permanent office in Cancun will help streamline the patient experience by providing holistic support throughout the treatment process.
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG) today announced that it will be opening a permanent office in Cancun, Mexico. The decision to expand its corporate presence into Cancun was based on the rising demand for patients seeking stem cells treatments at the group’s facilities already established in Cancun. The GSCG maintains two regenerative medicine operations in Cancun, which include medical facilities and a stem cells laboratory.
GSCG’s Cancun facilities provide state-of-the art options for patients seeking stem cells treatments that are currently not available in the US. While these protocols and products are currently unavailable within the US’s borders due to regulations, the Cancun center has still adopted the FDA’s frameworks for safe and effective regenerative medicine products and therapies. Guided by these protocols, physicians at the center deliver safe and effective stem cells therapies and products that can help patients suffering from degenerative diseases recover more quickly than with traditional treatment protocols.
With the establishment of a permanent office presence in Cancun, the GSCG seeks to provide a seamless holistic experience for patients seeking treatment at its facilities. With its office located near its medical center and laboratory, the GSCG team can more closely monitor the treatment process from the time the patient arrives at the Cancun airport to the time their treatment is complete and they return to the US.
“The Global Stem Cells Group is pleased to establish a permanent presence in Cancun with the opening of this new office location,” said Benito Novas, CEO of the Global Stem Cells Group. “By expanding our presence, we will be able to open up additional treatment opportunities for physicians in the US who may be limited by FDA regulations in ensuring their patients receive the critical stem cells therapies they need. US patients looking for relief from regenerative diseases are welcome at our Cancun center and will appreciate our state-of-the art facilities and top-notch care.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group to Break Ground on New Lab in Mexico
The new Stem Cells Lab is set to break ground in 2020, providing affordable regenerative medicine products to Latin America and the US
MIAMI LAKES, Florida—The Global Stem Cells Group today announced that it will be expanding its research and production efforts with a new lab in Mexico. The lab is the group’s first facility of its kind and will produce neonatal tissue-derived products such as exosomes, cord blood derived stem cells, and amniotic fluid derived products. Groundbreaking is slated for January 2020.
The Global Stem Cells Group is a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. To further the group’s mission, the new lab will fill a much-needed research and production niche in the regenerative medicine field and will be especially beneficial to physicians practicing in Latin America and the United States.
The lab will strictly adhere to all Good Manufacturing Practice (GMP) standards. Although the lab will be located in Mexico, all products will be procured and processed according to the standards and regulations set forth by the American Association of Tissue Banks (AATB) and the United States Food and Drug Administration (FDA). All tissue will come from local donors, with the lab strictly adhering to donor ethics and the FDA’s approved serological screening policies.
In addition to producing neonatal tissue derived products, the lab will also facilitate clinical trials to explore the safety and efficacy of new regenerative medicine products before they launch. The lab will also serve as a teaching and learning center for doctors and scientists across the globe looking to learn more about stem cells protocols.
“The Global Stem Cells Group is committed to facilitating stem cell research and medicine across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “Our new lab in Mexico will allow us to make good on this mission by delivering more affordable neonatal tissues derived products to doctors across Latin America and the US. As a result, more patients will find relief from debilitating degenerative diseases.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Adimarket, LLC Looks to Expand Market Reach with Launch of New PRP Product
The group’s new platelet-rich plasma (PRP) offering meets international standards for compliance, safety, and efficacy
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, today announced the availability of a new product that is a viable treatment option in a host of regenerative medicine sectors. With its new platelet-rich plasma (PRP) product, Adimarket will provide physicians with an exciting treatment protocol that can deliver relief to patients needing critical aesthetic, wound, and orthopedic care.
PRP is a super biological product of sorts, composed of a higher concentration of platelets than what is usually found in blood — 6-10 times more, on average. Adimarket’s PRP kit is the first of its kind in the stem cells and regenerative medicine industry, seeking to deliver higher platelet counts in an affordable and easy-to-use system. The revolutionary system is designed to shorten total processing time and reduce human error as it maximizes platelet concentration numbers. Adimarket’s offering has the capability of producing both leukocyte-rich and leukocyte-poor PRP and works in a variety of centrifuge systems.
PRP has been gaining interest and traction in the world of stem cell therapies and regenerative medicine. For clinicians working in the aesthetics, wound care, and orthopedic sectors, PRP has proven be a promising treatment option in offering relief to their patients.
In developing its PRP product, Adimarket researchers and scientists adhered to the highest international standards, making the product a viable option for physicians across the globe. With the launch of this new product, Adimarket is looking to expand its reach into new markets across the Middle East and Europe.
“Adimarket and its products have been met with great enthusiasm from physicians in the US and Latin America,” said Benito Novas, CEO of the Global Stem Cells Group. “With the launch of this new PRP product, our goal is to continue to serve our partners in those markets while expanding our presence into Europe and the Middle East. Our ultimate goal is to help more physicians across the globe deliver critical stem cell treatments to their patients, with the goal of alleviating unnecessary suffering.”
To learn more about Adimarket and to purchase its PRP product, visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Benito Novas of Aesthetica Marketing Group Set as Keynote for Chilean Aesthetics Congress
The keynote will highlight trends in social media marketing for physicians working in aesthetics
MIAMI LAKES, Florida—Benito Novas, CEO of Aesthetica Marketing Group (AMG), has been selected to serve as the keynote speaker at the upcoming Congreso del la Sociedad Chilena de Medicina y Estética. AMG, which is sponsoring the Chilean congress, is an American company focused on providing doctors working in the aesthetics medical industry practical solutions for their marketing challenges. The congress will be held on August 22-24, 2019 at the Hotel InterContinental Santiago in Santiago, Chile.
The annual event is the group’s main event, attracting physicians in the aesthetics medical industry across Chile and beyond. Novas’ keynote lecture will highlight current trends and best practices in social media and how physicians working in the aesthetics industry can better leverage social media in increasing the success of their practices.
During the congress, AMG will also launch two new courses focused on the aesthetics market, Pellet Therapy Certification and an IV/Chelation course.
The Pellet Therapy Certification course will provide practitioners with comprehensive clinical knowledge of this therapy option—one that is gaining rapid traction and recognition globally. Facilitators will present scientific reviews, case studies, and procedural training during the workshop. Attendees will be provided an in-depth introduction to pellet therapy, supported by reviews of clinical evidence on the need for customized dosing, in addition to assessing pellet dosing protocols for male and female patients. Pellet sterility, equipment, and what to look for in a compounding pharmacy will also be discussed.
AMG’s IV/Chelation course has been redesigned and now includes the most recent practices and protocols in intravenous nutritional therapies, in addition to chelation therapy in regard to its uses in lead toxicity and other heavy metals. Lecturers will not only cover the fundamentals of IV therapy and expand on the use of vitamins, minerals, amino acids, and other unique parenteral compounds but also review various aspects of integrating IV therapy into practice, as well as implementation strategies. Faculty presenters additionally will discuss potential application of the therapy in cancer treatment protocols, thus giving attendees the unique opportunity to learn about the most cutting-edge uses of IV therapy as a treatment method. At the conclusion of the course, clinicians will have a thorough understanding of how to perform IV therapy in both theory and practice.
To learn more about the upcoming Congreso del la Sociedad Chilena de Medicina y Estética or to register, visit https://sochimce.cl/congreso/. To learn more about Aesthetica Marketing Group, visit https://esteticamarketing.com/.
- Published in Press Releases
Adimarket, LLC Launches New Product for Physicians Seeking Regenerative Medicine and Stem Cell Centers
The comprehensive guide, “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” is available for purchase on Adimarket’s online store.
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, has launched a new product for physicians interested in starting regenerative medicine and stem cell treatment centers. The guide, entitled “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” provides physicians with valuable information to guide them through the process of proposing and setting up new centers in the industry.
The comprehensive guide provides physicians with a one-stop place to find information critical to setting up a treatment center and includes information about training, equipment installation, cellular product storage procedures, supply inventories, laboratory startup, and more. The guide covers both scientific and administrative training concepts to help enable physicians to start their own centers at the lowest cost possible.
By following the guide, clinic officials will be able to launch a center with a wide range of cell lineages and products available, as well as have at its disposal the industry’s leading patient treatment protocols and standard operating procedures used by the Global Stem Cells Group’s global clinical network.
“For physicians looking to add regenerative medicine protocols to their current practices, Adimarket’s guide is a must-have resource,” said Benito Novas, CEO of the Global Stem Cells Group. “Our hope is that our guide will give more physicians the knowledge, tools, and confidence necessary to offer regenerative medicine and stem cell treatments to their patients to help alleviate suffering.”
To learn more about Adimarket and to purchase the “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center,” visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
- Published in Press Releases